TrialPLoS medicine2020

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.

Delphine Sculier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.